United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - ticagrelor (unii: glh0314rvc) (ticagrelor - unii:glh0314rvc) - ticagrelor tablets are indicated to reduce the risk of cardiovascular death, myocardial infarction (mi), and stroke in patients with acute coronary syndrome (acs) or a history of mi. for at least the first 12 months following acs, it is superior to clopidogrel. ticagrelor tablets also reduce the risk of stent thrombosis in patients who have been stented for treatment of acs [see clinical studies (14.1)] . ticagrelor tablets are indicated to reduce the risk of a first mi or stroke in patients with coronary artery disease (cad) at high risk for such events [see clinical studies (14.2)]. while use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (t2dm). ticagrelor tablets are contraindicated in patients with a history of intracranial hemorrhage (ich) because of a high risk of recurrent ich in this population [see clinical studies (14.1), (14.2)] . ticagrelor tablets are contraindicated in patients with active pathological bleeding

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: purified water; croscarmellose sodium; calcium hydrogen phosphate dihydrate; magnesium stearate; mannitol; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - ticagrelor, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; mannitol; calcium hydrogen phosphate dihydrate; purified water; hyprolose; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - ticagrelor, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Canada - English - Health Canada

apotex inc - ticagrelor - tablet - 60mg - ticagrelor 60mg - platelet aggregation inhibitors

Canada - English - Health Canada

apotex inc - ticagrelor - tablet - 90mg - ticagrelor 90mg - platelet aggregation inhibitors

Canada - English - Health Canada

teva canada limited - ticagrelor - tablet - 60mg - ticagrelor 60mg - platelet aggregation inhibitors

Canada - English - Health Canada

teva canada limited - ticagrelor - tablet - 90mg - ticagrelor 90mg - platelet aggregation inhibitors

Canada - English - Health Canada

angita pharma inc. - ticagrelor - tablet - 60mg - ticagrelor 60mg

Canada - English - Health Canada

angita pharma inc. - ticagrelor - tablet - 90mg - ticagrelor 90mg

Canada - English - Health Canada

taro pharmaceuticals inc - ticagrelor - tablet - 60mg - ticagrelor 60mg - platelet aggregation inhibitors